Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01770353 · ClinicalTrials.gov registry record · Phase 1
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
A Phase 1 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01770353 is a Phase 1 study that has completed, run by Ipsen. The registered enrollment target is 45 participants.
The verdict
NCT01770353, a Phase 1 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
Interventions
- DRUG Ferumoxytol
- DRUG MM-398
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2012-11 |
| Est. Completion | 2018-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01770353
The ClinicalTrials.gov registry entry for NCT01770353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT01770353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01770353 about?
NCT01770353 is a clinical study titled "MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment". This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
What is the current status of trial NCT01770353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2012-11. Estimated completion is 2018-10-02.
What interventions are being tested in trial NCT01770353?
The interventions under investigation include: Ferumoxytol (DRUG), MM-398 (DRUG).
Who is sponsoring clinical trial NCT01770353?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.